Jump to content

MacroGenics Adopts Genedata Profiler to Enhance Development of Immunotherapies

Emerging leader in immuno-oncology therapeutics implements innovative software platform to design smarter clinical trials and accelerate development of precision medicines

April 19, 2021
Basel, Switzerland

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced a long-term partnership agreement with MacroGenics, a biopharmaceutical company and an emerging leader in developing and commercializing innovative immune-oncology therapeutics. The agreement provides MacroGenics with access to Genedata Profiler® and includes consulting services to support rapid adoption and integration of the platform into MacroGenics’ R&D infrastructure.

The deployment of Genedata Profiler strengthens MacroGenics’ capabilities to derive novel hypotheses from integrated datasets, from both proprietary and public sources, aiding the interpretation of biomarker data and the design of clinical trials.

The Genedata Profiler software provides MacroGenics with a comprehensive solution that addresses various challenges while providing additional opportunities including

  • Aggregation and curation of dispersed clinical and non-clinical research data, in a central repository, to create an institutional memory;
  • Self-service access to data and easy-to-use analytical tools empowers data scientists and clinicians to run complex analyses in a controlled and secure environment;
  • Cross-study and cross-technology data integration and analysis unlocks actionable insights and facilitates informed decision-making; and
  • Automated workflows for data harmonization, integration, and analytics streamlines and standardizes analytical processes, while ensuring data reproducibility.    

Beyond software, MacroGenics benefits from utilizing Genedata’s scientific domain expertise in data analytics and interpretation, IT support and scientific consulting, while maintaining full ownership of its proprietary data. The MacroGenics scientific team is working closely with Genedata experts to unravel the power of their data and advance their translational and clinical research programs.

“An in-depth understanding of biopharma R&D workflows coupled with deep bio-informatics expertise makes Genedata a trusted partner who offers not only a high-quality product but also agile consulting”, said Paul Moore, Ph.D., Vice-President of Immunology and Cell Biology at MacroGenics. “This partnership provides us with innovative approaches to drive the integration of biomarker data within and across our clinical programs including the digitalizing of translational workflows associated with clinical studies.”

The integrated, data-driven approach enabled by Genedata Profiler will empower MacroGenics to generate new scientific insights and hypotheses which will help:

  • Accelerate the discovery and development of predictive biomarkers indicative of therapy response to define the best subpopulation of patients to benefit from their immunotherapies,
  • Identify drugs’ specific indications to improve clinical trials inclusion criteria,
  • Determine the therapeutic mechanism of action (pharmacodynamics) to strengthen the rationale of the treatment regimen.

Already in use, Genedata Profiler has improved MacroGenics’ internal data organization and formatting. Data integration workflows and advanced analytics performed within the system have enhanced several ongoing translational/clinical studies and generated results in support of presentations at international conferences (ASCO, ASH). MacroGenics will continue the collaboration with Genedata to further enhance their analytical capabilities to support forward and reverse translational research.

“We are excited to enter into a strategic partnership with MacroGenics and help them maximize the value of Genedata Profiler for their translational and clinical research programs,” said Othmar Pfannes, Ph.D., CEO of Genedata. “We are committed to supporting emerging biopharma companies in their digital transformation, helping them to optimize their R&D processes, and facilitating data-driven decision-making. We believe that with Genedata Profiler we can positively impact not only biopharma internal organization but also clinical trial design bringing effective therapeutics faster to patients.”

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube


Allison Kurz
Public Relations


The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

This partnership provides us with innovative approaches to drive the integration of biomarker data within and across our clinical programs including the digitalizing of translational workflows associated with clinical studies.

Paul Moore, Ph.D.
Vice-President of Immunology and Cell Biology